四川科伦药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）于近日收 到公司控股股东刘革新先生关于其持有的公司部分股份质押及解除质押的通知， 相关情况具体如下： 一、股东股份解除质押的基本情况 证券代码：002422 证券简称：科伦药业 公告编 号：2025-039 | 股东姓 | | | 本次质押前 | 本次质押后 | | 占其所 | | 占公司 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 持股数量 | | 持股比 | | | | | 已质押股 | | | 份 | 占质押 | 未质押股份 | 占未质 | | | | | | | | | | 质押股份数 | 质押股份数 | | 持股份 | 总股本 | | | 名 | （股） | 例 | | | | | 限售数量 | | | 股份比 | 限售数量 | | 押股份 | | | | | | | | | | 量（股） | 量（股） | | 比例 | 比例 | | | | | ...

刘革新代言的产品为科伦药业旗下川宁生物的一款叫做"麦角硫因"的生物提取物，产品宣称具有抗衰功能。不过，有业内人士表示："这种物质的实际功效 以及应用的边界仍然需要进一步验证。" 近日，科伦药业董事长刘革新出现在一个保健品广告视频中。广告中，刘革新以"75岁刘先生"的"赤膊"形象出现，并称："没有什么不可能。" 七旬董事长"赤膊上阵"亲自带货，也折射出传统药企在新形势下面临的挑战。 据悉，刘革新代言的产品为科伦药业旗下川宁生物的一款叫做"麦角硫因"的生物提取物，产品宣称具有抗衰功能。不过，有业内人士表示："这种物质的实 际功效以及应用的边界仍然需要进一步验证。" 上个月，科伦药业财报显示，2025年一季度，公司实现营业收入43.9亿元，同比下降近30%；净利润5.84亿元，同比下滑超过43%；2022年至2024年，科伦 药业销售费已连续三年下滑，输液业务受集采影响是收入下降的重要原因。此外，川宁生物的原料药/中间体价格有所波动。 根据福布斯富豪榜最新数据，作为科伦药业的掌舵者，刘革新个人财富目前已经达到17亿美元（约合122.6万元人民币），较科伦药业上市首日55亿元人民 币的个人财富翻了一倍多。另据科伦药业 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-039 四川科伦药业股份有限公司 关于公司控股股东部分股份质押及解除质押的公告 刘革新先生上述股份质押不存在负担重大资产重组等业绩补偿义务的情 况。 三、股东股份累计质押的情况 截至本公告披露日，刘革新先生及其一致行动人所直接持有的股份质押情 况如下： 1 | 股东姓 | | | 本次质押前 | 本次质押后 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名 | 持股数量 （股） | 持股比 例 | 质押股份数 | 质押股份数 | 持股份 | 总股本 | 已质押股份 | 占质押 | 未质押股份 | 占未质 | | | | | 量（股） | 量（股） | 比例 | 比例 | 限售数量 | 股份比 | 限售数量 | 押股份 | | | | | | | | | （股）注 | 例 | （股）注 | 比例 | | 刘革新 | 379,128,280 | 23.72% | 106,014,00 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]

[Table_StockInfo] 2025 年 05 月 11 日 证券研究报告•2024 年报&2025 年一季报点评 当前价：34.14 元 科伦药业（002422）医药生物 目标价：——元（6 个月） 创新药核心品种获批，业绩短期承压 | [Table_MainProfit ] 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 21812.41 | 23601.63 | 25728.94 | 28732.85 | | 增长率 | 1.67% | 8.20% | 9.01% | 11.68% | | 归属母公司净利润（百万元） | 2935.89 | 2998.31 | 3376.55 | 3878.83 | | 增长率 | 19.53% | 2.13% | 12.62% | 14.88% | | 每股收益 EPS（元） | 1.84 | 1.88 | 2.11 | 2.43 | | 净资产收益率 ROE | 12.57% | 11.65% | 11.81% | 12.17% | | ...

Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

Core Viewpoint - The chairman of Kelun Pharmaceutical, Liu Gexin, has become a spokesperson for the company's products, showcasing his physique in a recent advertisement, which has garnered significant attention on social media [4][5]. Financial Performance - In 2024, Kelun Pharmaceutical achieved a revenue of 21.812 billion yuan, representing a year-on-year growth of 1.67%, and a net profit of 2.936 billion yuan, up 19.53%, both hitting historical highs [1][7]. - From 2021 to 2023, the company's revenue grew from 17.277 billion yuan to 21.454 billion yuan, with respective year-on-year growth rates of 4.94%, 9.46%, and 12.69% [7]. - The sales expenses for Kelun Pharmaceutical have decreased for three consecutive years, from 4.728 billion yuan in 2022 to 3.493 billion yuan in 2024, with changes of -5.86%, -5.89%, and -21.51% respectively [1][10]. Research and Development - Kelun Pharmaceutical has invested nearly 14.5 billion yuan in R&D since 2013, with R&D expenses increasing from 1.795 billion yuan in 2022 to 2.171 billion yuan in 2024, reflecting growth rates of 3.37%, 8.27%, and 11.68% [2][8]. - The company has a diverse product portfolio, with 684 varieties and 1,073 specifications of pharmaceutical products, including 143 varieties of infusion products [9]. Market Position and Strategy - Kelun Pharmaceutical is recognized as one of the largest pharmaceutical enterprises in China, with a comprehensive industry system spanning R&D, manufacturing, and distribution [3]. - The company is focusing on optimizing its infusion product structure and expanding its market coverage, benefiting from national drug procurement policies [8][10]. - Analysts express optimism about Kelun Pharmaceutical's innovative drug business contributing significant revenue in 2025, despite short-term pressures on its infusion business [11]. Dividend Policy - For the fiscal year 2024, Kelun Pharmaceutical plans to distribute a total dividend of 1.214 billion yuan, which accounts for 41.34% of its net profit [10].

Core Viewpoint - The marketing strategy of Kelong Pharmaceutical, led by Chairman Liu Gexin, reflects the company's urgent need to explore new business avenues due to declining traditional business growth [5][8]. Group 1: Product and Marketing Strategy - Kelong Pharmaceutical's product, "Ergothioneine Capsules," is positioned in the high-end dietary supplement market, priced at 1499 yuan per bottle, with each capsule containing 30mg of high-activity ergothioneine [3]. - The product claims to have 10-30 times the antioxidant capacity compared to traditional Vitamin C and Coenzyme Q10, targeting health needs related to anti-aging and cell protection [3][9]. - The marketing campaign features Chairman Liu Gexin, who at 75 years old, promotes the product with a strong physical image, aiming to create a compelling narrative around health and vitality [5][9]. Group 2: Financial Performance and Challenges - Kelong Pharmaceutical reported a significant decline in revenue for Q1 2025, with a total revenue of 4.39 billion yuan, down 29.42% year-on-year, and a net profit of 584 million yuan, down 43.07% [5][7]. - The core business segment, particularly infusion products, has been adversely affected by centralized procurement policies, leading to an 11.85% revenue decline in 2024 [5][8]. - Another subsidiary, Chuaning Bio, also faced challenges with a 15% decrease in revenue and an 18.26% drop in net profit for Q1 2025, impacted by regulatory constraints on antibiotic production [8]. Group 3: Strategic Vision and Future Outlook - Liu Gexin's personal commitment to the product, having used it for three years, and his disciplined lifestyle are intended to enhance the credibility of the marketing campaign [8]. - The company aims to integrate treatment and preventive medicine over the next three to five years, indicating a strategic shift towards a dual focus on health and innovation [8][9]. - The health sector is viewed as a "blue ocean" market, but the oral product market for ergothioneine is still in its early stages, requiring further validation of its efficacy [9].

以下文章来源于每日经济新闻 ，作者每经记者 每日经济新闻 . 中国主流财经全媒体。互联网新闻信息服务许可证编号：51120190017 。 5月8日晚间，科伦药业（002422.SZ，股价34.14元，市值545.58亿元）董事长刘革新在科伦集团官方视频号发布的一则广告中赤膊上 阵，展示健硕肌肉，为 公司旗下抗衰老产品"麦角硫因胶囊"代言。 广告中，75岁的刘革新肌肉线条分明，配以" 刘先生75岁——'没有不可能！ '"的广告词， 迅速在社交媒体引发热议，相关话题一度冲上 微博热搜。据界面新闻报道，经记者核实，该视频中出现的男子确为科伦药业董事长刘革新。 对此，有网友意见不一，有网友怀疑视频真实性，也有网友认为"比请明星代言、网红带货靠谱"。 据了解，除了刘革新，科伦药业内部也有员工使用了一段时间这款产品。 这款麦角硫因胶囊由科伦药业全资子公司"科伦永年"销售，在售版本定价1499元/瓶（60粒），每粒含30mg（毫克）麦角硫因。产品宣 传称其"清除自由基效果远超传统成分VC与辅酶Q10的10至30倍"，并称"科伦集团携日本百年企业匠心打造"。 值得一提的是，据媒体报道，科伦药业子公司川宁生物负责提供原料，生 ...

Core Viewpoint - Kelong Pharmaceutical's chairman, Liu Gexin, promotes the company's anti-aging product, "Methylthioadenosine Capsules," in a striking advertisement, showcasing his fitness at the age of 75, which has generated significant social media buzz [1][2]. Company Overview - Kelong Pharmaceutical (002422.SZ) has a market capitalization of 54.558 billion yuan and a stock price of 34.14 yuan [1]. - The company is exploring the health and wellness sector as a potential growth avenue, especially after experiencing a decline in revenue and net profit in the first quarter of the year [6]. Product Details - The "Methylthioadenosine Capsules" are marketed at 1,499 yuan per bottle (60 capsules), with each capsule containing 30 mg of the active ingredient [3]. - The product claims to have antioxidant effects that are 10 to 30 times more effective than traditional ingredients like Vitamin C and Coenzyme Q10 [3]. - The capsules are sold through online platforms and Japanese physical stores, with plans for further online sales on JD Overseas and Tmall International [6]. Marketing Strategy - Liu Gexin has been using the product for three years and maintains a strict fitness regimen, which the company emphasizes in its marketing [2][6]. - The advertisement has sparked discussions on social media, indicating a successful initial marketing impact [2]. Industry Context - The high-end anti-aging health product market is competitive, and consumer acceptance of the product's efficacy will take time to establish [6]. - Methylthioadenosine is gaining attention in the skincare and health supplement sectors for its potential anti-aging properties, although large-scale human trial data is still limited [6][7].